Scinovex
articleTop 10% cited

Immunological Events in Regressing Genital Warts

American Journal of Clinical Pathology · 1994 · Vol. 102(6) · pp. 768–774
Nicholas ColemanH BirleyAdrian RentonNashat HannaBalvinder K. RyaitMicheline ByrneD Taylor‐RobinsonMargaret Stanley

Abstract

Little is known of the in vivo role of the immune system in controlling human papillomavirus infection in the genital tract. The authors have studied 125 closely monitored patients with genital warts. Of these 125 patients, wart regression was seen in 28 patients. This study provides evidence that clearance of human papillomavirus from the genital tract is characterized by an active cell-mediated immune response. Regressing warts (n = 14) contained significantly more T lymphocytes (P < .05, Wilcoxon rank sum test) and macrophages (P < .01) than did nonregressing controls (n = 14). CD4-positive lymphocytes predominated in regression, both within the wart stroma and the surface epithelium, where there was a significant change in the ratio of CD4+ to CD8+ cells (P < .01). Lymphocytes in regression also showed greater expression of activation markers, and the majority were of the "antigen-experienced" phenotype. There was no difference in Langerhans cell numbers, although there was significant induction of the immune accessory molecules HLA-DR and ICAM1 (P < .05) on keratinocytes, and E-selectin and VCAM1 (P < .05) on endothelial cells in regressing warts. The changes in regression are consistent with a delayed-type hypersensitivity reaction to foreign antigen, and the ability to induce and mount such a response may be a critical determinant of effective natural immunity to the genital HPVs. Specific targeting of delayed-type hypersensitivity responsiveness may increase the efficacy of strategies for immuno-intervention against HPV infection in the genital tract.

Cell Adhesion Molecules ResearchImmunotherapy and Immune ResponsesT-cell and B-cell ImmunologyGenital wartsSex organMedicineImmunologyDermatologyPathologyBiologySyphilisHuman immunodeficiency virus (HIV)

MeSH terms

AdultCondylomata AcuminataFemaleFollow-Up StudiesGenital Diseases, FemaleGenital Diseases, MaleHLA-DR AntigensHumansImmunity, CellularMaleRemission, SpontaneousT-LymphocytesAntigens, CDPapillomaviridae
Citations
486
FWCI
2.88
field-weighted impact
References
23
Percentile
92%
vs. same field & year
Citations per year
Cited by
Human Papillomavirus and Cervical Cancer
Clinical Microbiology Reviews · 2003 · 2,393 citations
Immune responses to human papillomavirus
Vaccine · 2005 · 589 citations
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.